Nanogen to Re-Brand, Sell Drug Tests Made by American Bio Medica in POC Setting | GenomeWeb
NEW YORK (GenomeWeb News) – Nanogen today said it will market point-of-care tests for drugs of abuse made by American Bio Medica into the "hospital-related" setting.
 
Nanogen will re-brand the tests under its Tox STATus name and sell them using its existing sales force and distribution network. American Bio Medica will continue to sell the tests under their original brand to its core criminal justice and workplace markets, a spokesperson for the company said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.